PVI
RIGL icon

Pura Vida Investments’s Rigel Pharmaceuticals RIGL Stock Holding History

Pura Vida Investments’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-60,000
Closed -$2.12M – 112
2018
Q1 		$2.12M Buy
+60,000
New +$2.4M 1.25% 27

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pura Vida Investments's RIGL Position: Q1 2019 in Review

Pura Vida Investments sold out of Rigel Pharmaceuticals (RIGL) in Q1 2019, closing a stake of 33,206 shares — an estimated $764K sold.

Pura Vida Investments first reported a position in RIGL in Q4 2017 and held it in 5 quarters. The position peaked at $2.35M in Q4 2017. 131 funds tracked by Wall St. Rank hold RIGL as of Q1 2019.

  • Pura Vida Investments reported no remaining Rigel Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Pura Vida Investments sold 33,206 Rigel Pharmaceuticals shares in Q1 2019, an estimated $764K.
  • Pura Vida Investments first reported a position in Rigel Pharmaceuticals in Q4 2017 and held it in 5 quarters.
  • Pura Vida Investments's Rigel Pharmaceuticals position peaked at $2.35M in Q4 2017.
  • 131 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2019.

Based on Pura Vida Investments's 13F filing for Q1 2019, filed 14 May 2019.